Polymorphisms in the ABCB1 gene in phenobarbital responsive and resistant idiopathic epileptic border collies

Journal of Veterinary Internal Medicine

Volumn 25, Issue 3, 2011, Pages 484-489

  Alves, L ^a   Hulsmeyer V ^b   Jaggy, A ^a   Fischer, A ^b   Leeb, T ^a   Drogemuller M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Drug resistance; Epilepsy; MDR1; Permeability glycoprotein; Single nucleotide polymorphisms

Indexed keywords

ANTICONVULSIVE AGENT; GLYCOPROTEIN P; PHENOBARBITAL;

ALLELE; ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MYOCLONUS EPILEPSY;

ALLELES; ANIMALS; ANTICONVULSANTS; DOG DISEASES; DOGS; DRUG RESISTANCE; EPILEPSIES, MYOCLONIC; GENE EXPRESSION REGULATION; P-GLYCOPROTEIN; PHENOBARBITAL; POLYMORPHISM, GENETIC;

ANIMALIA; CANIS FAMILIARIS;

EID: 79955521023     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.0718.x     Document Type: Article

References (48)

1. Chandler K. Canine epilepsy: What can we learn from human seizure disorders? Vet J 2006;172:207-217.
2. Lane SB, Bunch SE. Medical management of recurrent seizures in dogs and cats. J Vet Intern Med 1990;4:26-39.
3. Thomas WB. Seizures and narcolepsy. In: Dewey CW, ed. A Practical Guide to Canine and Feline Neurology. Ames, IA: Iowa State Press; 2008:193-212.
4. Kwan P, Brodie MJ. Emerging drugs for epilepsy. Expert Opin Emerg Drugs 2007;12:407-422.
5. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602.
6. Lazarowski A, Czornyj L, Lubienieki F, et al. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007;48:140-149.
7. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 2010;51:1069-1077.
8. Volk HA, Matiasek LA, Luján Feliu-Pascual A, et al. The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. Vet J 2008;176:310-319.
9. von Klopmann T, Rambeck B, Tipold A. Prospective study of zonisamide therapy for refractory IE in dogs. J Small Anim Pract 2007;48:134-138.
10. Schrickx JA, Fink-Gremmels J. Implications of ABC transporters on the disposition of typical veterinary medicinal products. Eur J Pharmacol 2008;585:510-519.
11. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
12. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-2524.
13. Rizzi M, Guiso G, Mulé F, et al. Induction of mdr-1 by limbic seizures in mice: Relevance for drug resistance in epilepsy. Soc Neurosci Abstr 2001;27:553-552.
14. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005;46:224-235.
15. Hung CC, Chen CC, Lin CJ, et al. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics 2008;18:390-402.
16. Basic S, Hajnsek S, Bozina N, et al. The influence of C3435 T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008;17:524-530.
17. Mealey KL, Bentjen SA, Gay JM, et al. Ivermectin sensitivity in Collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001;11:727-733.
18. Muñana KR, Nettifee-Osborne JA, Bergman RL Jr, et al. Association between the ABCB1 (MDR1) gene and seizure control in canine epilepsy. ACVIM Abstracts, Anaheim, CA, 2010;159A:237.
19. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14.
20. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16:197-201.
21. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-528.
22. Takane H, Kobayashi D, Hirota T, et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 2004;311:1179-1187.
23. Hülsmeyer V, Zimmermann R, Brauer C, et al. Epilepsy in Border Collies: Clinical manifestation, outcome, and mode of inheritance. J Vet Intern Med 2010;24:171-178.
24. Geyer J, Döring B, Godoy JR, et al. Development of a PCR-based diagnostic test detecting a nt230 (del4) MDR1 mutation in dogs: Verification in a moxidectin-sensitive Australian Shepherd. J Vet Pharmacol Therap 2005;28:95-99.
25. Baars C, Leeb T, von Klopmann T, et al. Allele-specific polymerase chain reaction diagnostic test for the functional MDR1 polymorphism in dogs. Vet J 2008;177:394-397.
26. Barret JC, Fry B, Maller J, et al. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
27. Karriker M. Genetic predisposition to adverse drug events in dogs. Vet Focus 2007;17:11-17.
28. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
29. Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005;2:86-98.
30. Schmidt D, Löscher W. Drug resistance in epilepsy: Putative neurobiologic and clinical mechanisms. Epilepsia 2005;46:858-877.
31. Seegers U, Potschka H, Löscher W. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res 2002;51:257-268.
32. Löscher W, Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res 2002;50:3-16.
33. West CL, Mealey KL. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. Am J Vet Res 2007;68:1106-1110.
34. Seegers U, Potschka H, Löscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 2002;451:149-155.
35. Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118:417-429.
36. Geyer J, Döring B, Godoy JR, et al. Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. J Vet Pharmacol Ther 2005;28:545-551.
37. Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc 2008;233:921-924.
38. Hugnet C, Bentjen SA, Mealey KL. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of Collies from France. J Vet Pharmacol Ther 2004;27:227-229.
39. Neff MW, Robertson KR, Wong AK, et al. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the Collie lineage. Proc Natl Acad Sci USA 2004;101:11725-11730.
40. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478.
41. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002;54:1295-1310.
42. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33.
43. Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistance. J Neurosci 2002;22:5833-5839.
44. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-1448.
45. Xiao-Dong L, Zhi-Hong Y, Hui-Wen Y. Repetitive/temporal hypoxia increased P-gp expression in cultured rat brain microvascular endothelial cells in vitro. Neurosci Lett 2008;432:184-187.
46. Baltes S, Gastens AM, Fedrowitz M, et al. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007;52:333-346.
47. Kennerly EM, Idaghdour Y, Olby NJ, et al. Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs. Pharmacogenet Genomics 2009;19:911-922.